Sökning: WFRF:(Karlén Anders)
> (2020-2024) >
Clinical effectiven...
Clinical effectiveness of golimumab in ulcerative colitis : a prospective multicentre study based on the Swedish IBD Quality Register, SWIBREG
-
- Eriksson, Carl, 1981- (författare)
- Örebro universitet,Örebro University,Karolinska Institute,Institutionen för medicinska vetenskaper,Region Örebro län,Department of Gastroenterology, Faculty of Medicine and Health, Örebro University, Örebro, Sweden; Clinical Epidemiology Division, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden,Orebro Univ, Sweden; Karolinska Inst, Sweden
-
- Visuri, Isabella, 1991- (författare)
- Örebro universitet,Örebro University,Institutionen för medicinska vetenskaper,Department of Gastroenterology,Orebro Univ, Sweden
-
- Vigren, Lina (författare)
- GHP Gastro Center Skåne, Lund, Sweden,GHP Gastro Ctr Skane, Sweden
-
visa fler...
-
- Nilsson, Linda (författare)
- Department of Gastroenterology, Danderyd Hospital, Stockholm, Sweden,Danderyd Hosp, Sweden
-
- Kärnell, Anders (författare)
- Merck Sharp and Dohme (Sweden) AB, Stockholm, Sweden
-
- Hjortswang, Henrik (författare)
- Linköpings universitet,Linköping University,Department of Gastroenterology and Department of Clinical and Experimental Medicine, Linköping University, Linköping, Sweden,Avdelningen för diagnostik och specialistmedicin,Medicinska fakulteten,Region Östergötland, Mag- tarmmedicinska kliniken
-
- Bergemalm, Daniel, 1977- (författare)
- Örebro universitet,Örebro University,Institutionen för medicinska vetenskaper,Region Örebro län,Department of Gastroenterology,Orebro Univ, Sweden
-
- Almer, Sven (författare)
- Karolinska Institutet,Karolinska Inst, Sweden,Karolinska University Hospital
-
- Hertervig, Erik (författare)
- Department of Gastroenterology, Skåne University Hospital, Lund, Sweden,Skane Univ Hosp, Sweden
-
- Karlén, Per (författare)
- Department of Gastroenterology, Danderyd Hospital, Stockholm, Sweden,Danderyd Hosp, Sweden
-
- Strid, Hans (författare)
- South Elfsborg Hospital,Department of Internal Medicine, Södra Älvsborg Hospital, Borås, Sweden,Sodra Alvsborg Hosp, Sweden
-
- Halfvarson, Jonas, 1970- (författare)
- Örebro universitet,Örebro University,Institutionen för medicinska vetenskaper,Department of Gastroenterology,Orebro Univ, Sweden
-
Bark, Lars Åke (creator_code:cre_t)
-
- Grip, Olof (creator_code:cre_t)
- Lund University,Lunds universitet,Internmedicin - epidemiologi,Forskargrupper vid Lunds universitet,Internal Medicine - Epidemiology,Lund University Research Groups
-
Thörn, Mari (creator_code:cre_t)
-
visa färre...
-
(creator_code:org_t)
-
- 2021-08-20
- 2021
- Engelska.
-
Ingår i: Scandinavian Journal of Gastroenterology. - : Informa UK Limited. - 0036-5521 .- 1502-7708. ; 56:11, s. 1304-1311
- Relaterad länk:
-
http://dx.doi.org/10... (free)
-
visa fler...
-
https://www.tandfonl...
-
https://doi.org/10.1...
-
https://liu.diva-por... (primary) (Raw object)
-
https://lup.lub.lu.s...
-
https://doi.org/10.1...
-
https://urn.kb.se/re...
-
http://kipublication...
-
https://urn.kb.se/re...
-
visa färre...
Abstract
Ämnesord
Stäng
- Objectives: Clinical trials demonstrated that golimumab is effective in anti-TNF naïve patients with ulcerative colitis. We aimed to assess the clinical effectiveness of golimumab in a real-world setting. Materials and methods: This was a prospective cohort study, conducted at 16 Swedish hospitals. Data were collected using an electronic case report form. Patients with active ulcerative colitis, defined as Mayo endoscopic subscore ≥2 were eligible for inclusion. The primary outcomes were clinical effectiveness at 12 weeks and 52 weeks, i.e. response (defined as a decrease in Mayo score by ≥3 points or 30% from baseline) and remission (defined as a Mayo score of ≤2 with no individual subscores >1). Results: Fifty patients were included. At study entry, 70% were previously exposed to anti-TNF, 16% to vedolizumab, and 96% to immunomodulators. The 12 and 52-week drug continuation rates were 37/50 (74%) and 23/50 (46%), respectively. The 12-week response rate was 14/50 (28%), the remission rate, 8/50 (16%) and the corresponding figures at week 52 were 13/50 (26%) and 10/50 (20%). Among patients who continued golimumab, the median Mayo score decreased from 7 (6–9) at baseline to 1 (0–5) at 52 weeks (p <.01) and the faecal calprotectin decreased from 862 (335–1759) µg/g to 90 (34–169) µg/g (p <.01). Clinical response at week 12 was highly predictive of clinical remission at week 52 (adjusted OR: 73.1; 95% CI: 4.5‒1188.9). Conclusions: The majority of golimumab treated patients represented a treatment refractory patient-group. Despite this, our results confirm that golimumab is an effective therapy in ulcerative colitis.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Gastroenterologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Gastroenterology and Hepatology (hsv//eng)
Nyckelord
- clinical effectiveness
- Golimumab
- inflammatory bowel disease
- ulcerative colitis
- Golimumab
Publikations- och innehållstyp
- art (ämneskategori)
- ref (ämneskategori)
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Eriksson, Carl, ...
-
Visuri, Isabella ...
-
Vigren, Lina
-
Nilsson, Linda
-
Kärnell, Anders
-
Hjortswang, Henr ...
-
visa fler...
-
Bergemalm, Danie ...
-
Almer, Sven
-
Hertervig, Erik
-
Karlén, Per
-
Strid, Hans
-
Halfvarson, Jona ...
-
Bark, Lars Åke
-
Grip, Olof
-
Thörn, Mari
-
visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
-
och Gastroenterologi
- Artiklar i publikationen
-
Scandinavian Jou ...
- Av lärosätet
-
Lunds universitet
-
Örebro universitet
-
Karolinska Institutet
-
Linköpings universitet